Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer

Tamara King, Anna Vardanyan, Lisa Majuta, Ohannes Melemedjian, Raymond B Nagle, Anne E Cress, Todd W Vanderah, Josephine Lai, Frank Porreca

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Metastatic bone cancer causes severe pain that is primarily treated with opioids. A model of bone cancer pain in which the progression of cancer pain and bone destruction is tightly controlled was used to evaluate the effects of sustained morphine treatment. In cancer-treated mice, morphine enhanced, rather than diminished, spontaneous, and evoked pain; these effects were dose-dependent and naloxone-sensitive. SP and CGRP positive DRG cells did not differ between sarcoma or control mice, but were increased following morphine in both groups. Morphine increased ATF-3 expression only in DRG cells of sarcoma mice. Morphine did not alter tumor growth in vitro or tumor burden in vivo but accelerated sarcoma-induced bone destruction and doubled the incidence of spontaneous fracture in a dose- and naloxone-sensitive manner. Morphine increased osteoclast activity and upregulated IL-1β within the femurs of sarcoma-treated mice suggesting enhancement of sarcoma-induced osteolysis. These results indicate that sustained morphine increases pain, osteolysis, bone loss, and spontaneous fracture, as well as markers of neuronal damage in DRG cells and expression of pro-inflammatory cytokines. Morphine treatment may result in "add-on" mechanisms of pain beyond those engaged by sarcoma alone. While it is not known whether the present findings in this model of osteolytic sarcoma will generalize to other cancers or opioids, the data suggest a need for increased understanding of neurobiological consequences of prolonged opioid exposure which may allow improvements in the use of opiates in the effective management of cancer pain.

Original languageEnglish (US)
Pages (from-to)154-168
Number of pages15
JournalPain
Volume132
Issue number1-2
DOIs
StatePublished - Nov 2007

Fingerprint

Bone Neoplasms
Spontaneous Fractures
Bone Fractures
Sarcoma
Morphine
Bone and Bones
Pain
Diagnosis-Related Groups
Opioid Analgesics
Osteolysis
Therapeutics
Naloxone
Opiate Alkaloids
Neoplasms
Osteoclasts
Tumor Burden
Interleukin-1
Femur
Cytokines
Incidence

Keywords

  • Cancer
  • Cancer pain
  • IL-1
  • Opiate receptors
  • Opioid hyperalgesia
  • Osteoclast

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Neuroscience(all)
  • Pharmacology
  • Clinical Psychology

Cite this

Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. / King, Tamara; Vardanyan, Anna; Majuta, Lisa; Melemedjian, Ohannes; Nagle, Raymond B; Cress, Anne E; Vanderah, Todd W; Lai, Josephine; Porreca, Frank.

In: Pain, Vol. 132, No. 1-2, 11.2007, p. 154-168.

Research output: Contribution to journalArticle

King, Tamara ; Vardanyan, Anna ; Majuta, Lisa ; Melemedjian, Ohannes ; Nagle, Raymond B ; Cress, Anne E ; Vanderah, Todd W ; Lai, Josephine ; Porreca, Frank. / Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. In: Pain. 2007 ; Vol. 132, No. 1-2. pp. 154-168.
@article{fc6b1594ba7c44e187b4cfba38cdc20a,
title = "Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer",
abstract = "Metastatic bone cancer causes severe pain that is primarily treated with opioids. A model of bone cancer pain in which the progression of cancer pain and bone destruction is tightly controlled was used to evaluate the effects of sustained morphine treatment. In cancer-treated mice, morphine enhanced, rather than diminished, spontaneous, and evoked pain; these effects were dose-dependent and naloxone-sensitive. SP and CGRP positive DRG cells did not differ between sarcoma or control mice, but were increased following morphine in both groups. Morphine increased ATF-3 expression only in DRG cells of sarcoma mice. Morphine did not alter tumor growth in vitro or tumor burden in vivo but accelerated sarcoma-induced bone destruction and doubled the incidence of spontaneous fracture in a dose- and naloxone-sensitive manner. Morphine increased osteoclast activity and upregulated IL-1β within the femurs of sarcoma-treated mice suggesting enhancement of sarcoma-induced osteolysis. These results indicate that sustained morphine increases pain, osteolysis, bone loss, and spontaneous fracture, as well as markers of neuronal damage in DRG cells and expression of pro-inflammatory cytokines. Morphine treatment may result in {"}add-on{"} mechanisms of pain beyond those engaged by sarcoma alone. While it is not known whether the present findings in this model of osteolytic sarcoma will generalize to other cancers or opioids, the data suggest a need for increased understanding of neurobiological consequences of prolonged opioid exposure which may allow improvements in the use of opiates in the effective management of cancer pain.",
keywords = "Cancer, Cancer pain, IL-1, Opiate receptors, Opioid hyperalgesia, Osteoclast",
author = "Tamara King and Anna Vardanyan and Lisa Majuta and Ohannes Melemedjian and Nagle, {Raymond B} and Cress, {Anne E} and Vanderah, {Todd W} and Josephine Lai and Frank Porreca",
year = "2007",
month = "11",
doi = "10.1016/j.pain.2007.06.026",
language = "English (US)",
volume = "132",
pages = "154--168",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer

AU - King, Tamara

AU - Vardanyan, Anna

AU - Majuta, Lisa

AU - Melemedjian, Ohannes

AU - Nagle, Raymond B

AU - Cress, Anne E

AU - Vanderah, Todd W

AU - Lai, Josephine

AU - Porreca, Frank

PY - 2007/11

Y1 - 2007/11

N2 - Metastatic bone cancer causes severe pain that is primarily treated with opioids. A model of bone cancer pain in which the progression of cancer pain and bone destruction is tightly controlled was used to evaluate the effects of sustained morphine treatment. In cancer-treated mice, morphine enhanced, rather than diminished, spontaneous, and evoked pain; these effects were dose-dependent and naloxone-sensitive. SP and CGRP positive DRG cells did not differ between sarcoma or control mice, but were increased following morphine in both groups. Morphine increased ATF-3 expression only in DRG cells of sarcoma mice. Morphine did not alter tumor growth in vitro or tumor burden in vivo but accelerated sarcoma-induced bone destruction and doubled the incidence of spontaneous fracture in a dose- and naloxone-sensitive manner. Morphine increased osteoclast activity and upregulated IL-1β within the femurs of sarcoma-treated mice suggesting enhancement of sarcoma-induced osteolysis. These results indicate that sustained morphine increases pain, osteolysis, bone loss, and spontaneous fracture, as well as markers of neuronal damage in DRG cells and expression of pro-inflammatory cytokines. Morphine treatment may result in "add-on" mechanisms of pain beyond those engaged by sarcoma alone. While it is not known whether the present findings in this model of osteolytic sarcoma will generalize to other cancers or opioids, the data suggest a need for increased understanding of neurobiological consequences of prolonged opioid exposure which may allow improvements in the use of opiates in the effective management of cancer pain.

AB - Metastatic bone cancer causes severe pain that is primarily treated with opioids. A model of bone cancer pain in which the progression of cancer pain and bone destruction is tightly controlled was used to evaluate the effects of sustained morphine treatment. In cancer-treated mice, morphine enhanced, rather than diminished, spontaneous, and evoked pain; these effects were dose-dependent and naloxone-sensitive. SP and CGRP positive DRG cells did not differ between sarcoma or control mice, but were increased following morphine in both groups. Morphine increased ATF-3 expression only in DRG cells of sarcoma mice. Morphine did not alter tumor growth in vitro or tumor burden in vivo but accelerated sarcoma-induced bone destruction and doubled the incidence of spontaneous fracture in a dose- and naloxone-sensitive manner. Morphine increased osteoclast activity and upregulated IL-1β within the femurs of sarcoma-treated mice suggesting enhancement of sarcoma-induced osteolysis. These results indicate that sustained morphine increases pain, osteolysis, bone loss, and spontaneous fracture, as well as markers of neuronal damage in DRG cells and expression of pro-inflammatory cytokines. Morphine treatment may result in "add-on" mechanisms of pain beyond those engaged by sarcoma alone. While it is not known whether the present findings in this model of osteolytic sarcoma will generalize to other cancers or opioids, the data suggest a need for increased understanding of neurobiological consequences of prolonged opioid exposure which may allow improvements in the use of opiates in the effective management of cancer pain.

KW - Cancer

KW - Cancer pain

KW - IL-1

KW - Opiate receptors

KW - Opioid hyperalgesia

KW - Osteoclast

UR - http://www.scopus.com/inward/record.url?scp=34848824654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848824654&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2007.06.026

DO - 10.1016/j.pain.2007.06.026

M3 - Article

C2 - 17706870

AN - SCOPUS:34848824654

VL - 132

SP - 154

EP - 168

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1-2

ER -